Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 24, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $380.00 to $19,195,500.00.

Highlighted Stocks Traded by Insiders:

Gordman's Stores (GMAN) - FREE Research Report

Tuchman Kenneth I, who is Director at Gordman's Stores, bought 2,500 shares at $5.33 on March 24, 2015. Following this transaction, the Director owned 5,000 shares meaning that the stake was boosted by 100% with the 2,500-share transaction.

The shares most recently traded at $5.89, up $0.56, or 9.51% since the insider transaction. Historical insider transactions for Gordman's Stores go as follows:

  • 4-Week # shares bought: 2,995
  • 12-Week # shares bought: 2,995
  • 24-Week # shares bought: 2,995

The average volume for Gordman's Stores has been 74,000 shares per day over the past 30 days. Gordman's Stores has a market cap of $103.8 million and is part of the services sector and retail industry. Shares are up 101.47% year-to-date as of the close of trading on Tuesday.

Gordmans Stores, Inc. operates department stores under the Gordmans name in the United States. Its merchandise selection includes a range of apparel, footwear, and home fashions products, as well as accessories. Currently, there is 1 analyst who rates Gordman's Stores a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GMAN - FREE

TheStreet Quant Ratings rates Gordman's Stores as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, generally high debt management risk, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Gordman's Stores Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Antares Pharma (ATRS) - FREE Research Report

Jacob Leonard S, who is Director at Antares Pharma, sold 23,500 shares at $2.68 on March 24, 2015. Following this transaction, the Director owned 168,885 shares meaning that the stake was reduced by 12.22% with the 23,500-share transaction.

The shares most recently traded at $2.59, down $0.09, or 3.55% since the insider transaction. Historical insider transactions for Antares Pharma go as follows:

  • 4-Week # shares bought: 40,000
  • 12-Week # shares bought: 40,000
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 25,000

The average volume for Antares Pharma has been 748,600 shares per day over the past 30 days. Antares Pharma has a market cap of $351.8 million and is part of the health care sector and health services industry. Shares are up 3.11% year-to-date as of the close of trading on Tuesday.

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. Currently, there are 3 analysts who rate Antares Pharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATRS - FREE

TheStreet Quant Ratings rates Antares Pharma as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Antares Pharma Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Marcus & Millichap (MMI) - FREE Research Report

Phoenix Investments Holdings LLC, who is 10% Owner at Marcus & Millichap, sold 600,000 shares at $31.99 on March 24, 2015. Following this transaction, the 10% Owner owned 20.6 million shares meaning that the stake was reduced by 2.84% with the 600,000-share transaction.

The shares most recently traded at $35.16, up $3.17, or 9.01% since the insider transaction. Historical insider transactions for Marcus & Millichap go as follows:

  • 4-Week # shares sold: 3.2 million
  • 12-Week # shares sold: 3.2 million
  • 24-Week # shares sold: 4.0 million

The average volume for Marcus & Millichap has been 192,100 shares per day over the past 30 days. Marcus & Millichap has a market cap of $1.3 billion and is part of the financial sector and real estate industry. Shares are up 6.59% year-to-date as of the close of trading on Tuesday.

Marcus & Millichap, Inc., a brokerage company, provides investment brokerage and financing services to sellers and buyers of various types and sizes of commercial real estate assets in the United States and Canada. The company has a P/E ratio of 27.8. Currently, there is 1 analyst who rates Marcus & Millichap a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMI - FREE

TheStreet Quant Ratings rates Marcus & Millichap as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Marcus & Millichap Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null